Jun 12, 2024

DEP® presentation at SNMMI radiopharmaceuticals conference (ASX Announcement)

DEP® presentation at SNMMI radiopharmaceuticals conference (ASX Announcement)

Melbourne, Australia; 11 June 2024: Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® radiotheranostics scientific poster presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada, overnight. The scientific poster presents data from Starpharma’s DEP® HER2 radiotheranostics program, demonstrating the promising utility of DEP® dendrimers in precision radiotheranostics for cancer imaging and therapeutic applications.

The SNMMI Annual Meeting is a leading scientific research event in nuclear medicine and molecular imaging, where developments in radiopharmaceuticals are a key focus. The conference offered Starpharma a valuable opportunity to present data on its radiotheranostics program and to network with interested companies.

Building on Starpharma’s previously reported preclinical results, the scientific poster presents new dosimetry analyses, showing that DEP® HER2 achieved significant tumour accumulation, with 20-30% of the injected dose per gram localising in tumour from day 1 to 5. This is comparable to trastuzumab, a monoclonal antibody marketed under the brand name Herceptin®. DEP® HER2 was distributed more rapidly to tumour than trastuzumab and was cleared more rapidly from the blood, resulting in less exposure to radiosensitive organs/tissue such as bone marrow, heart, and lungs. Due to its lower biodistribution in bone marrow, DEP® HER2 could potentially deliver 1.7 times more radioactivity to the tumour than the trastuzumab antibody, demonstrating the ability of DEP® dendrimers to enhance tumour targeting in drug delivery.

Overall, the results from Starpharma’s radiotheranostics program continue to demonstrate that DEP® dendrimers are a promising, versatile, and multifunctional platform for customising precision radiotheranostics for cancer imaging and therapeutic applications, bridging the gap between small molecules and large antibodies. DEP® HER2 is a priority program for Starpharma.

The DEP® radiotheranostics scientific poster presentation is appended. Co-authors on the poster were Professor Kris Thurecht and his team from The University of Queensland’s Centre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR Hub).


View/download the ASX Announcement: DEP® presentation at SNMMI radiopharmaceuticals conference.

 This contains certain forward-looking statements.